To the Editor With interest we read the article by Chatterjee et al,1 who performed a meta-analysis to quantitatively assess the rates of intracranial hemorrhage (ICH) occurring in randomized trials investigating the new oral anticoagulants (NOACs) dabigatran, rivaroxaban, and apixaban in patients with atrial fibrillation. They found that each of the 3 drugs reduced the risk for ICH and concluded that any of the currently available NOACs can be considered first line for patients at high risk for ICH.
Stöllberger C, Finsterer J. Establishing Comparable Requirements and Treatment Groups Before Applying Statistical Comparison. JAMA Neurol. 2014;71(3):369-370. doi:10.1001/jamaneurol.2013.5966